AKI - CKD Transition Development Program
Acute Kidney Injury to Chronic Kidney Disease progression
Key Facts
About Delta4 AI
Delta4 AI is a private, preclinical-stage Austrian TechBio company founded in 2018, specializing in AI-driven drug repurposing and indication expansion. Its proprietary Hyper-C platform integrates systems biology, computational modeling, and AI to analyze large-scale biological data, uncovering new therapeutic applications for existing drugs, particularly for rare and complex diseases. The company operates a hybrid business model, offering both platform services to clients and advancing its own internal pipeline of preclinical and clinical programs, primarily focused on kidney diseases, oncology, and Long COVID. Delta4 has gained recognition from Austrian research agencies and partners with platforms like Scientist.com to streamline research collaborations.
View full company profile